WebAug 11, 2024 · Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024 August 11, 2024, 4:05 PM · 11 min read Announced strategic collaboration with Roche, with a $110... WebJun 30, 2024 · The Company anticipates an IND filing and initiation of a Phase 1 clinical trial for P-CD19CD20-ALLO1 in the first half of 2024. Poseidawill receive $110.0 millionupfront from Roche and could receive up to $110.0 millionin near-term fees and …
Roche New Frontiers of Cell Therapy
WebAug 3, 2024 · Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies. 08/03/2024 at 7:30 AM EDT. Download PDF. Leveraging Poseida's novel approach to cell therapy and … WebApr 11, 2024 · SAN DIEGO, April 11, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. PSTX, a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare ... dr juan ross martinez ut
Roche Grasps at Alzheimer’s and Goes Big on Blood Cancers with …
WebAug 4, 2024 · Roche will receive either exclusive rights or options to develop and commercialise a few allogeneic CAR-T programs in Poseida’s portfolio, with an IND expected in 2024. The programs include P-BCMA-ALLO, an allogeneic CAR-T therapy for multiple … WebAug 3, 2024 · Leveraging Poseida's novel approach to cell therapy and Roche's expertise in developing and commercializing therapies to transform cancer care, the collaboration is focused on advancing... WebAug 3, 2024 · Under the agreement, Roche will receive from Poseida either exclusive rights or options to develop and commercialize a number of allogeneic CAR-T programs in Poseida's portfolio that are directed ... dr juan romero